p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells

Paclitaxel (PTX) is a chemotherapeutic agent that is used to treat a variety of cancers, including non-small cell lung cancer (NSCLC). However, the emergence of drug resistance limits the utility of PTX. This study determined the signaling pathway that contributes to PTX resistance. We first establi...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Park, Shin-Hyung, Seong, Myeong-A, Lee, Ho-Young
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4884985/
https://ncbi.nlm.nih.gov/pubmed/26799187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6945
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items